聚肌苷酸诱导的早期原发性胆汁性肝硬化小鼠模型的建立*

doi:10.3969/j.issn.1672-5069.2014.06.015

Abstract

Abstract: Objective To establish an animal model of early primary biliary cirrhosis （PBC） by injection of polyinosinic-polycytidylic acid（Poly I:C）. Methods Thirty female C57BL/6 mice were randomly divided into model and control group. Mice in model group were injected with poly I:C at a dose of 5 mg.kg^-1 while animals in control with equal volume of saline for 24 weeks. The antimitochondrial antibody-M2（AMA-M2）,CD4⁺CD25⁺Foxp³⁺ cells were detected at 8,16 and 24 weeks. Histological changes of liver samples were evaluated with HE, PASM,and masson trichrom staining and CK19 was detected by anti-CD19 antibody staining at each stage. Results The positive rate of AMA-M2 in model group at week 24 was 100%（5/5）,significantly higher than in the control group（0/5）;The percentages of CD4⁺CD25⁺Foxp³⁺ Tregs in the peripheral blood in model group at week 8,16 and 24 were（3.48±0.95）%,（3.30±1.55）% and（2.67±0.97）%,all of which significantly lower than those in the control group at each corresponding time[（7.25±1.63）%,（6.33±1.06）% and（5.58±1.52）%,P<0.05];The expression of CK19 in liver tissues showed no significant difference between the two groups;Liver pathology showed progressively increased infiltration of inflammatory cells around the portal area and bile duct,small bile duct proliferation,bilious fragmental necrosis and bridging fibers in model group. Conclusions The animal model of early PBC is successfully established by injection of Poly I:C and the CD4⁺CD25⁺Foxp3⁺ T cells may play a critical role in the pathogenesis of the entity.

Key words: Primary biliary cirrhosis, Polyinosinic-polycytidylic acid, Mouse, Animal model

Guo Xiaoxia, Li Liangxue, Wu Yupeng. Establishment of a mouse model of early primary biliary cirrhosis by polyinosinic-polycytidylic acid[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 619-623.

References

[1] Talwalkar JA,Souto E,Jorgensen RA,et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol, 2003,1（4）:297-302.
[2] Hirschfield GM. Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol,2011,25（6）:701-712.
[3] 段维佳,贾继东.原发性胆汁性肝硬化的诊断和治疗.胃肠病学,2009,14（4）:209-213.
[4] 马欢,王邦茂. 原发性胆汁性肝硬化动物模型研究进展. 国际消化病杂志,2012,32（2）:93-95.
[5] Concepcion AR,Medina JF. Approaches to the pathogenesis of primary biliary cirrhosis through animal models. Clinics Res Hepatol Gastroenterol,2012,36（1）:21-28.
[6] 许良中,杨文涛.免疫组织化学反应结果的判断标准.中国癌症杂志,1996,6（4）:229-231.
[7] Soslow RA,Dannenberg AJ,Rush D,et al. Cox-2 is expressed in human pulmonary,colonic,and mammary tumors. Cancer,2000,89（12）:2637-2645.
[8] Lleo A,Invernizzi P,Mackay IR,et al. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol,2008,14（21）:3328-3337.
[9] McNally RJ,James PW,Ducker S,et al. Seasonal variation in the patient diagnosis of primary biliary cirrhosis:further evidence for an environmental component to etiology. Hepatology,2011,54（6）:2099-2103.
[10] Invernizzi P,Selmi C,Gershwin ME. Update on primary biliary cirrhosis. Dig Liver Dis,2010,42（6）:401-408.
[11] 刘然,陆伦根. 抗线粒体抗体对原发性胆汁性肝硬化诊断价值研究进展. 实用肝脏病杂志,2014,17（2）:218-221.
[12] Braun D,Geraldes P,Demengeot J. Type I interferon controls the onset and severity of 232232autoimmune manifestations in lpr mice. J Autoimmun,2003,20（1）:15-25.
[13] 自身免疫性肝病诊断和治疗指南.中华医学会风湿病学分会.中华风湿病学杂志,2011,15（8）:556-558.
[14] Hsia CC,Evarts RP,Nakatsukasa H,et al. Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology,1992,16（6）:1327-1333.
[15] Kaplan MM,Gershwin ME. Primary biliary cirrhosis. N Engl J Med,2005,353（12）:1261-1273.
[16] Bernuzzi F,Fenoglio D,Battaglia F,et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun,2010,35（3）:176-180.
[17] 刘娟,曹雪涛. 2012年度免疫学研究重要进展. 中国免疫学杂志,2013,29（1）:3-13.
[18] Ramsdell F. Foxp3 and natural regulatory T cells:key to a cell lineage. Immunity,2003,19（2）:165-168.
[19] 许茵,杨小娟,蒯守刚. 原发性胆汁性肝硬化患者外周血CD4 + CD25 + Foxp 3+ 调节性T细胞检测及其临床意义. 中国实验诊断学,2014,18（4）:592-594.
[20] Muratori L,Longhi MS. The interplay between regulatory and effector T cells in autoimmune hepatitis:Implications for innovative treatment strategies. J Autoimmun,2013,46（17）:74-80.

Establishment of a mouse model of early primary biliary cirrhosis by polyinosinic-polycytidylic acid

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[2]	Liu Yingchuan, Zhao Pengcheng, You Ting, et al.. Changes of peripheral blood 25-（OH） 2-D3 levels and peripheral T lymphocyte subsets in patients with primary biliary cirrhosis receiving vitamin D supplementation and ursodeoxycholic acid treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 907-910.
[3]	Liu Jinguo, Wang Baokui. Efficacy of Fufangbiejia Ruanganpian and ursodeoxycholic acid combination in the treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 340-343.
[4]	Qin Wei, Chen Yuping, Yang Zhao, et al. Expression of transforming growth factor β-1 in liver tissues of patients with primary biliary cirrhosis and its relationship with liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 237-240.
[5]	Chen Xiaojun, Song Yang. Changes of peripheral blood T lymphocyte subsets and efficacy of ursodesoxycholic acid and vitamin D combination in treatment of patients with primary biliary cholangitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 80-83.
[6]	Tao Mingling, Zhang Shibin, Wu Yanjing, et al.. Non-invasive predictors of esophageal varices in patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 439-442.
[7]	Liu Funa, Liu Jiangkui, Shen Yihui.. Efficacy of ursodeoxycholic acid and prednisolone combination in treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 443-446.
[8]	Guo Rui, Tan Jin.. A randomized controlled trial of ursodeoxycholic acid in treating patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 109-110.
[9]	Han Yongbin， Liu Xin，Wang Aifang， et al.. Primary biliary cirrhosis misdiagnosed as bone marrow hyperplasia syndrome: A case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 747-748.
[10]	Hao Jianhong,Hao Haiyan,Hu Yiling. Clinical features of primary biliary cirrhosis: An analysis of 94 cases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 352-353.
[11]	Zhou Xinren, Wang Fang, Yun Shenghao. Intrahepatic transplantation of umbilical cord blood stem cells in treatment of patients with decompensated primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 219-220.
[12]	Wang Gui， Wang Jiangbin.. Features of elderly patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 573-574.
[13]	Kong Xianglu，Guo Xiaoxia. Systemic review of Chinese herbal medicine combined with ursodeoxycholic acid in treatment of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 379-382.
[14]	Li Pingying，Lu Lungen. Advances in pharmacotherapy of patients with primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 441-444.
[15]	Chen Jing, Jia Gui, Gao Zhengjun, et al.. Smoking and primary biliary cirrhosis:A case-control study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 164-167.